# Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma

> **NCT03927157** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 405 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** Experimental: Tezepelumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03927157
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-14
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-08-13
- **Target enrollment:** 405 (ACTUAL)
- **Last updated:** 2025-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03927157

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03927157, "Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03927157. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*